PROSTATA BEZI XAVFSIZ GIPERPLAZIYASINI MONO VA KOMPLEKS DAVOLASH
Keywords:
prostata bezi xavfsiz giperplaziyasi, pastki siydik yo‘llari simptomlari, alfa-adrenoblokatorlar, 5-alfa-reduktaza ingibitorlari, kombinatsiyalangan terapiya.Abstract
Prostata bezi xavfsiz giperplaziyasi– keksa yoshdagi erkaklarda pastki siydik yo‘llari simptomlarining eng keng tarqalgan sababi hisoblanadi. Kasallikning patogenezi androgenlar, yallig‘lanish, stromal-epitelial o‘zaro ta’sir va o‘sish omillari bilan bog‘liq murakkab biologik jarayonlarga asoslanadi. Zamonaviy davolash strategiyasi simptomlar og‘irligi, prostata hajmi, asoratlar mavjudligi va bemorning hayot sifatini inobatga olgan holda individual tarzda tanlanadi.
References
1.European Association of Urology. EAU Guidelines on the Management of Non-neurogenic Male LUTS, incl. Benign Prostatic Obstruction. Arnhem: EAU Guidelines Office; 2023.
2.American Urological Association. Management of Benign Prostatic Hyperplasia (BPH). AUA Guideline. Linthicum (MD): AUA; 2023.
3.McVary KT, Roehrborn CG, Avins AL, et al. Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol. 2011;185(5):1793–1803.
4.Roehrborn CG. Benign prostatic hyperplasia: an overview. Rev Urol. 2005;7(Suppl 9):S3–S14.
5.The New England Journal of Medicine. Barry MJ, Roehrborn CG. Benign prostatic hyperplasia. N Engl J Med. 2001;344(2):99–105.
6.Gratzke C, Bachmann A, Descazeaud A, et al. EAU guidelines on the assessment of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol. 2015;67(6):1099–1109.
7.Roehrborn CG, Siami P, Barkin J, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol. 2010;57(1):123–131.
8.European Urology. Oelke M, Bachmann A, Descazeaud A, et al. Guidelines on the treatment and follow-up of non-neurogenic male LUTS. Eur Urol. 2013;64(1):118–140.
9.Kaplan SA. Re: phosphodiesterase type 5 inhibitors in the treatment of LUTS secondary to BPH. J Urol. 2012;187(4):1194–1195.
10.Nickel JC. Inflammation and benign prostatic hyperplasia. Urol Clin North Am. 2008;35(1):109–115.